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Objective: Large preloads of protein and fat have been shown to lower glucose after a carbohydrate-rich meal in
people with type 2 diabetes but add a considerable energy burden. Low calorie preloads [<5% of daily energy
intake] have been tested in this study in people with prediabetes and with type 2 diabetes.
Research design and methods: This was an unblinded randomised crossover study with two placebo days and
two active treatment days. Glucose was measured for 3 hours with fingerprick samples as well as continuous
glucose monitoring [CGMS]. Twenty-four subjects with pre-diabetes or moderately controlled type 2 diabetes
[fasting glucose < 10 and HbA1c < 8.5%] were recruited. The preload contained 17 g whey protein plus 3 g lactose
and 5 g guar, and 1 g flavour material [including sucralose] dissolved in 150 ml cold water or 150 ml cold water
with no additives. The breakfast test meal consisted of 2 slices of bread, margarine and jam [3 slices for men] with
the test drink 15 minutes beforehand.
Results: Peak fingerprick glucose was reduced by 2.1 mmol/L at 45 min [p < 0.0001]. Average fingerprick glucose
over 3 hours was reduced by 0.8 mmol/L [p = 0.0003]. There was no difference between those with diabetes or
prediabetes or those on medication or not on medication.
Conclusions: An 80 kcal whey protein/fibre preload can lower average glucose over 3 hours by 0.8 mmol/L. If used
long term before at least two carbohydrate-rich meals/day this preload could lower HbA1c by up to 1%.
Trial registration: The trial was registered with the Australian New Zealand Clinical Trials Registry number
ACTRN12612001251819.
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At least 50% of people with type 2 diabetes have poor
glucose control despite drug treatment and are often
faced with the prospect of the addition of another oral
drug or insulin. Medical nutrition therapy involving life-
style modification is recommended as the first line of
management for this disease [1] but can also have sig-
nificant effects on glucose control later in the disease
[2]. However, patient compliance is often poor. Dietary
strategies include modifications in fat and complex
carbohydrate intake or low glycaemic index (GI) diets,* Correspondence: peter.clifton@unisa.edu.au
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unless otherwise stated.all of which can be difficult to follow or maintain [3]. An
alternative approach is the use of a 55 g whey preload
drink which can slow gastric emptying and increases in-
sulin, glucagon like peptide-1 (GLP1) and glucose inhibi-
tory peptide release and lowers glucose by 3 mmol/L [4].
An alternative approach involves the use of 15-30 g glu-
tamine which also lowers postprandial glucose by 0.3 to
1 mmol/L [5]. Fibres such as pectin [6] and guar [7] re-
duce gastric emptying but pectin tends to lower insulin
without an effect on glucose levels in normal subjects
while guar lowers both in people with diet controlled
type 2 diabetes. Fat may also be used to slow gastric
emptying and enhance GLP1 secretion which delays and
lowers the glucose peak by 1 mmol/L but at a cost of an
extra 240 kcal added to the meal [8].Ltd. This is an Open Access article distributed under the terms of the Creative
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of whey and replacing some of the protein with guar
would be just as effective at lowering postprandial glu-
cose as 55 g of whey alone. Guar alone in dose of 4 g
twice daily has been shown in one study to lower Hba1c
by 0.6% suggesting that flattening of the postprandial




Confirmed prediabetes or type 2 diabetes from fasting
glucose or oral glucose tolerance test performed by
general practitioner
Fasting glucose less than or equal to 10
HbA1c less than 8.5%
Diet or metformin only
No restriction on age or BMI
Exclusion criteria
Attempting to lose weight or restrict caloric intake
Use of insulin or any other medication except metformin
Twenty-four subjects with pre-diabetes or moderately
well -controlled type 2 diabetes were recruited by news-
paper advertisement between July and December 2013.
These participants consisted of 13 people with type 2 DM
and 11 with prediabetes. One subject had a fasting blood
glucose of 10 mmol/L while all the rest were under
9 mmol/L. Ethics approval was from the Human Ethics
committee of the Alfred Hospital (number 416/12) and all
volunteers gave written informed consent. The trial was
registered with the Australian New Zealand Clinical Trials
Registry number ACTRN12612001251819.
Preload
The preload contained 17 g whey protein plus 3 g lac-
tose and 5 g guar, and 1 g flavour material (including
non-caloric sweetener either stevia or sucralose) dis-
solved in 150 ml cold water or 150 ml cold water alone.
Protocol
The study was an unblinded 5-day continuous glucose
monitoring (CGMS) study and an acute post meal fin-
gerprick blood glucose study. Four finger prick tests
were also conducted per day for optimal performance of
the monitor. Six visits to the clinic were required with
the first day for insertion and stabilisation of the moni-
tor and the next 4 days for meal/drink tests. A packaged
pre-test meal was provided the night before each test to
standardise conditions. All morning medications were
taken at least 15 minutes before the test drink.Test meal
The breakfast test meal consisted of 2 slices of bread,
margarine and jam (3 slices for men) plus tea/coffee if
desired, with a test drink 15 minutes beforehand. Tea
and coffee intake for each individual was standardised to
be consistent across all 4 visits. This test drink consisted
of 150 ml of cold water mixed with 17 g of protein plus
5 g of fibre (the active drink) or 150 ml of plain cold
water (control). The order of these two pre-meal drinks
was selected at random. The active drink was taken on
two of these days, and water on the other two days.Glucose assessment
The iPRO2 blinded CGMS (Medtronics Australasia) was
inserted into the abdominal skin on a Monday after-
noon. Once the signal was stable an initial fingerprick
blood glucose was taken and the volunteer then went
home with a prepackaged evening meal. All fingerprick
glucose values were recorded on a paper log with the
time of recording and returned to the clinic every
24 hours. CGMS values were taken every 5 minutes for
5 days but this analysis was confined to 3 hours after the
preload to match the fingerprick data. Values from both
tests and control days were averaged.Fingerprick test
Fingerpricks were taken before the breakfast and then
every 15 min for the first hour, then at 90 min, 120 min
and 180 min. Values from the two treatment and two
control days were averaged.Statistics
The primary hypothesis was that the protein/fibre would
lower the peak glucose by 1 mmol/L compared with the
water and we had 99% power, p < 0.001 to show a glu-
cose lowering of 1 mmol/L for the fingerprick tests (SD
0.6 mmol/L from a previous pilot study). Randomisation
was performed using a random number generator for
treatment pairs (ie treatment/control for days 1 and 2
and treatment/control for days 3 and 4). Peak change
was calculated manually as the timing of the peak varied
from person to person and with treatment. The whole
curve over 3 hours was also analysed using repeated
measures ANOVA with diabetes status and medication
as between subject factors and fasting glucose as a co-
variate. Paired t tests were also used to examine each
time point in the fingerprick tests if the overall curves
were different by repeated measures ANOVA. Average
glucose over 3 hours was calculated as a time weighted
average of all 8 fingerprick points and all time points
from the CGMS (equivalent to AUC). Data is shown as
mean +/SD.
Clifton et al. Nutrition Journal 2014, 13:103 Page 3 of 5
http://www.nutritionj.com/content/13/1/103Results
Baseline characteristics of participants
There were 6 men and 5 women who had prediabetes,
with an average age of 60 and a BMI of 32. One was
treated with metformin. There were 7 men and 6 women
with diabetes with an average age of 60 and a BMI of 32.
Nine were treated with metformin.
Fingerprick glucose
The control and treatment curves were different by re-
peated measures ANOVA (Figure 1, Treatment p < 0.001,
time p < 0.001, time by treatment p < 0.001). Blood glucose
was reduced by 1.1 mmol/l at 15 min (p = 0.003),
1.3 mmol/L at 30 min (p = 0.001), 2.1 mmol/L at 45 min
(p = 7 × 10−5) and 1.7 mmol/L at 60 minutes (p = 0.0007)
and 1 mmol/L at 90 min (p = 0.02). It was higher by
0.25 mmol/L at 120 min (NS) and 0.84 mmol/L at 180 min
(p = 0.003). Peak glucose was reduced by 1.4 mmol/L
(p < 0.001) and the summated peak was shifted by 30
minutes. Average glucose over 3 hours was reduced by
0.77 mmol/L (p = 0.0003).
There was no difference in response between the
people with type 2 DM and prediabetes and there was
no relationship between fasting glucose response and
the effect of the drink.
CGMS: The average effect of the drink was a peak re-
duction of 1.04 mmol/L (p < 0.0001) with the effect ran-
ging from +1.3 mmol/L to −2.3 mmol/L (Figure 2). The
average CGMS glucose over 3 hours was lowered by
0.7 mmol/L (p < 0.001). Seven individuals showed no
peak reduction and five showed no delay in peak. There
was no effect beyond 3 hours. There were no adverse ef-














Figure 1 Blood glucose over 180 min by finger prick. Fingerpricks were
180 minutes. The two control and two treatment test days were averaged.
between the curves and the repeated measures ANOVA was significantly d
treatment p < 0.001).Discussion
The premeal protein/fibre drink clearly lowers the peak
and average glucose over three hours and delays the
peak as well, demonstrating it could be a useful therapy
to add to patients with prediabetes or diabetes not opti-
mally controlled by diet or diet plus metformin. The
average lowering of nearly 1 mmol/l over 3 hours with a
peak reduction of 2 mmol/L is exactly equivalent to [10]
or greater than [11] the effect of sitagliptin on acute glu-
cose profile. Sitagliptin can lower HbA1c by an average
of 0.7% compared with placebo [12]. This finding with
sitagliptin matches the findings with dietary carbohy-
drate where in 901 free living patients with type 2 dia-
betes those in the lowest quintile of glycemic index and
glycemic load had an HbA1c 1% lower than those in the
highest quintile and the difference in post meal glucose
at one hour between these groups was about 2 mmol/L
[13]. This premeal protein/fibre drink treatment would
appear to outperform low GI meal planning but long
term data is not yet available so we do not know how
well patients will comply with a pre-meal drink regimen
long term. In the Jenkins low GI- 6 month study in type
2 diabetes [14], Hba1c was lowered by 0.32%. The differ-
ence between the diets was 13 GI units. A meta-analysis
of 16 studies using GI in meal planning showed an aver-
age reduction in HbA1c of 0.27% (p = 0.03) and fructosa-
mine of 0.1 mmol/L (p = 0.05) [15].
Whey drinks fed 30 minutes before an ad libitum pizza
in young healthy men show a clear dose response from
10-40 g of whey with a peak reduction of 1.8 mmol/L with
20 g whey at 30 minutes after the meal. Thirty g of whey
was similar but 40 g of whey reduced glucose by





taken before the test drink and then at 15, 30, 45, 60, 90, 120 and
All time points except 120 minutes were significantly different
















Figure 2 Blood glucose over 180 min by continuous glucose monitoring. Blood glucose values were calculated every 5 minutes. The two
control and two treatment test days were averaged. The repeated measures ANOVA was significantly different (Treatment p < 0.001, time
p < 0.001, time by treatment p < 0.001).
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duced by 13-30% accounting for some of the glucose re-
duction. Glucose reduction with 17 g of whey was greater
in the current study and although not formally tested the
addition of guar to whey would appear to add to its glu-
cose lowering effect. In another study in 14 healthy, lean
subjects 9 g of whey protein isolate taken immediately be-
fore a fixed meal lowered glucose at 45 min by 2.6 mmol/
L and elevated insulin and GLP1 [17].
The mechanism of the effect on postprandial glucose
would appear to be via slowing gastric emptying from
both guar [7] and protein [4] as well as via protein in-
duced insulin release [4,5]. With 55 g of whey Ma et al.
[4] demonstrated a 3 fold increase in insulin at 90 mi-
nutes while Samoch-Bonetet al. [5] showed that 15 g of
glutamine increased insulin from 450 to 600 pmol/L and
delayed the insulin peak from 30 to 60 minutes and its
effect was more marked than 100 mg of sitagliptin. Guar
alone in a dose of 4 g twice daily has been shown in one
study to lower Hba1c by 0.6% suggesting this degree of
flattening of the postprandial glycemic profile with guar
alone can lead to long term glucose lowering and clinic-
ally useful effects [9]. Thus with the treatment described
in this paper we would anticipate an equal contribution
from protein and guar to glucose lowering although we
did not set out to specifically elucidate the separate and
combined effects of whey and guar but only tested a
practical combination drink. GLP1 and PYY are elevated
by whey more than by glucose preloads before a pizza
meal [18] suggesting GLP1 may be important in the ef-
fect of the drink.In terms of cardiovascular complications a 1 hour
postprandial glucose level predicts myocardial infarction
and death in people with newly diagnosed with type 2
diabetes [19]. In both men and women with diabetes
who had myocardial infarctions a post lunch difference
of about 2 mmol/L (time not specified) was seen com-
pared with people without disease [20]. In a meta-
analysis of 7 acarbose studies (an alpha-glucosidase
inhibitor which reduces glucose absorption) 1 hour post-
prandial glucose was reduced by 1.6 mmol/L and 2 h
glucose by 2.2 mmol/l while HbA1c was reduced by
0.6% and myocardial infarctions were reduced by 64%.
Acarbose also reduced weight, triglyceride and systolic
blood pressure [21]. Thus in this study the effect on
1 hour glucose is equivalent to acarbose but the drink is
unlikely to have an effect on triglyceride and blood pres-
sure but it may reduce weight long term. Although
acarbose causes abdominal discomfort because of co-
lonic fermentation of carbohydrate this did not occur in
this study as we believe carbohydrate absorption was
slowed but not inhibited to any degree. We are currently
performing a 6 month randomised controlled trial exam-
ining the effect of a protein/fibre pre meal drink on
HbA1c, weight and blood lipids.
In conclusion we have demonstrated that a low calorie
protein/fibre drink acutely lowers glucose by 2 mmol/L in
people with prediabetes and type 2 diabetes and thus could
be a potential long term dietary strategy to reduce the gly-
cemic impact of high carbohydrate meals. The drink is pal-
atable and could be used on a daily or twice daily basis but
we have no data on long term compliance yet.
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